SYDNEY, Jan. 8, 2014 /PRNewswire/ -- Novogen Limited
(ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today
announced that Graham Kelly, Ph.D.,
its Executive Chairman and Chief Executive Officer, is
scheduled to present a company overview to investors,
pharmaceutical and healthcare executives attending the Biotech
Showcase™ 2014, taking place January 13-15,
2014 in San Francisco,
Calif.
(Logo:
http://photos.prnewswire.com/prnh/20131220/NY36990LOGO )
Slides to accompany the presentation will be available for
download on Monday, January 13 on the
Novogen website.
Details of the presentation are as follows:
Date: Tuesday, January 14,
2014
Time: 2:00 p.m. PST
Place: Parc 55 Wyndham San Francisco, Union Square
Track: C - Room Mission II
About Novogen Limited
Novogen is a public, Australian biotechnology company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in
New Haven, Connecticut. The
Company has two main drug technology platforms known as
super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs
target cancer stem cells and are being developed for the treatment
of ovarian cancer and glioblastoma. ATM drugs target the cancer
cell cytoskeleton and are being developed for the treatment of
melanoma, prostate cancer and neuroblastoma. Novogen has entered
into a joint venture with Yale
University known as CanTx Inc. with the aim of developing
personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website,
www.novogen.com.
SOURCE Novogen Limited